Yuanyuan Zhao
YOU?
Author Swipe
View article: Supplementary Figure S4 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Figure S4 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Fig. S4 The relationship between baseline EGFR/HER3 expression and best response in patients
View article: Data from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Data from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Purpose:Izalontamab (SI-B001) is a novel EGFR×HER3 bispecific antibody. This first-in-human phase I study presents the safety and pharmacokinetics of izalontamab.Patients and Methods:Previously treated patients with locally advanced or met…
View article: Supplementary Figure S3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Figure S3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Fig. S3 The waterfall plot depicts the best objective responses concerning the tumor size in the efficacy analysis set.
View article: Supplementary Methods S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Methods S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Text. Inclusion and exclusion criteria
View article: Supplementary Figure S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Figure S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Fig. S1 Pharmacokinetics of Izalontamab
View article: Supplementary Table S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S1. Baseline clinical characteristics in different dose groups
View article: Supplementary Table S2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S2. Representativeness of Study Participants
View article: Figure 3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Figure 3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Typical radiographic images of the patient who achieved PR. A and B, A 41-year-old patient with HNSCC achieved PR after two cycles of izalontamab 16 mg/kg one dose per week treatment. SYSU Cancer Center, Sun Yat-sen Universit…
View article: Supplementary Figure S2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Figure S2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Fig. S2 Swimmer plots of responses to treatment and the duration of treatment in efficacy analysis set.
View article: Supplementary Table S4 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S4 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S4. Treatment-emergent adverse events of Izalontamab
View article: Supplementary Table S3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S3. Adverse events in different dose groups
View article: Table 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Table 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Most common TRAEs.
View article: Figure 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Figure 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Dose concentration–time plot of izalontamab concentration at different dosage regimens. A, Izalontamab concentration–time profile at C1D1. B, Izalontamab concentration–time profile at C1D22. C1D1, cycle 1 day 1; C1D22, cycle …
View article: Table 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Table 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Baseline demographic and clinical characteristics.
View article: Supplementary Table S5 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S5 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S5. Pharmacokinetic Parameter Summary of Izalontamab (Visit C1D22)
View article: Figure 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Figure 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Study design of the clinical study. *Doses of 0.4 and 1.2 mg/kg were administered using an accelerated titration design.
View article: Supplementary Table S7 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S7 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S7. Details of Rash and Paronychia at different doses
View article: Supplementary Table S6 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Supplementary Table S6 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Supplementary Table S6. Summary of anti-drug antibody
View article: Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial Open
View article: Genitourinary system related tumors and coronary atherosclerosis risk: Evidence from a Mendelian randomization study on multi-cohorts
Genitourinary system related tumors and coronary atherosclerosis risk: Evidence from a Mendelian randomization study on multi-cohorts Open
View article: Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis
Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis Open
Perioperative, adjuvant and neoadjuvant chemoimmunotherapy were all suitable for patients with stage IB-II NSCLC, while perioperative and neoadjuvant chemoimmunotherapy may represent more favorable options for stage III disease. In patient…
View article: Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials
Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials Open
View article: Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study Open
View article: Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors
Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors Open
CVL218, a novel poly ADP‐ribose polymerase (PARP1/2) inhibitor, has strong PARP1/2 selective inhibitory activity and high oral bioavailability. We aimed to assess the safety and tolerability of CVL218 in patients with pretreated advanced s…
View article: Predicting microvascular invasion plus cytokeratin 19 expression positivity in hepatocellular carcinoma based on EOB-MRI using multitask deep learning
Predicting microvascular invasion plus cytokeratin 19 expression positivity in hepatocellular carcinoma based on EOB-MRI using multitask deep learning Open
Aim: To construct and validate a multitask deep learning (DL) model based on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) contrast-enhanced magnetic resonance imaging (MRI) for predicting microvascular invasion…
View article: Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study Open
Purpose: Izalontamab (SI-B001) is a novel EGFR×HER3 bispecific antibody. This first-in-human phase I study presents the safety and pharmacokinetics of izalontamab. Patients and Methods: Previously treated patients with locally advanced or …
View article: A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial Open
View article: Successful Distal Radial Artery Puncture for Invasive Arterial Blood Pressure Monitoring in Hemodynamically Unstable Patients
Successful Distal Radial Artery Puncture for Invasive Arterial Blood Pressure Monitoring in Hemodynamically Unstable Patients Open
View article: The Methylation and Expression of LINC00511, an Important Angiogenesis-Related lncRNA in Stomach Adenocarcinoma
The Methylation and Expression of LINC00511, an Important Angiogenesis-Related lncRNA in Stomach Adenocarcinoma Open
Stomach adenocarcinoma (STAD) has high incidence and mortality rates. Long non-coding RNAs (lncRNAs) and angiogenesis are closely related to the pathogenesis and metastasis of STAD. Recently, emerging evidence demonstrated that DNA methyla…
View article: Differences in Salinity Tolerance in Avena sativa and Avena nuda
Differences in Salinity Tolerance in Avena sativa and Avena nuda Open
Both Avena sativa and Avena nuda, which are highly valued for their use in food and fodder, demonstrate considerable potential in the management of saline-alkali soils. This study aimed to establish a foundation for the selection of salt-t…